Dannielle Appelhans to lead Cour

Autoimmune and inflammatory disease company Cour Pharmaceuticals Development Co. Inc. said COO Dannielle Appelhans will become president, CEO and board member on Sept. 1. Appelhans will succeed John Puisis, who will continue with the company as a board member and adviser until Dec. 31; a COO successor was not disclosed. Appelhans joined Cour in 2023 from Rubius Therapeutics Inc. (NASDAQ:RUBY), where she was CEO. 

Context Therapeutics Inc. (NASDAQ:CNTX), which is developing bispecifics to treat solid tumors, hired Claudio Ullmann as CMO and Karen Andreas as VP, clinical operations. Ullmann and Andreas both join from Avenge Bio Inc., where they had the same job titles. ...